![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C26H31ClFN5O4S |
Molar mass | 564.07 g·mol−1 |
3D model (JSmol) | |
| |
|
ADSB-FUB-187 is anindazole-basedsynthetic cannabinoid. It is a potentagonist of theCB1 receptor with abinding affinity ofKi = 0.09 nM and anEC50 of 1.09 nM.[1] It was originally developed byPfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms ofKi, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[2]
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-marketsynthetic cannabis products.[3]
![]() | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |